Avapritinib Approved for GIST Subgroup.

The FDA approved avapritinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors with mutations in exon 18 of PDGFRA-genetic alterations that render tumors insensitive to all previously approved therapies for this rare sarcoma of the digestive tract. ©2020 American Association for Cancer Research.